Difference between revisions of "Cisplatin (Platinol)"
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf Cisplatin package insert (8/2011)]</ref><ref>[http://hemonc.org/docs/packageinsert/cisplatin.pdf Cisplatin package insert (locally hosted backup)]</ref> | Class: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf Cisplatin package insert (8/2011)]</ref><ref>[http://hemonc.org/docs/packageinsert/cisplatin.pdf Cisplatin package insert (locally hosted backup)]</ref> | ||
Revision as of 19:11, 5 December 2011
General information
Class: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Extravasation: vesicant (concentration >=0.5 mg/mL)/irritant (concentration <0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
Regimens
Standard format will be:
<acronym (if any)> (generic drug1, generic drug2, generic drug3, etc.) (disease)
List of regimens containing cisplatin